Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06577155
PHASE2

Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty

Sponsor: Asklepieion Voulas General Hospital

View on ClinicalTrials.gov

Summary

60 patients ASA I-III, undergoing total hip arthroplasty were randomly assigned, into one of two groups, namely group E (n=30), where levobupivacaine will be administeral intrathecally ; and group N (n=30), where levobupivacaine plus nalbuphine will be administeral intrathecally. All patients will receive a standardized multimodal analgesic regimen, including a PENG block and PCA morphine. Morphine consumption during the first 24 hours postoperatively will be measured and additionally the investigators will record: Time of morphine first dose administration, NRS scores in static and dynamic conditions in 4 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours and 48 hours postoperatively, complications, patient satisfaction and duration of hospitalization.

Official title: The Effect of Nalbuphine as an Adjuvant to Levobupivacaine in Subarachnoid Anesthesia in Total Hip Arthroplasty. A Double-blind, Randomized, Controlled Study.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-09-01

Completion Date

2025-06

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DRUG

Levobupivacaine

Regional anesthesia / analgesia

DRUG

Levobupivacaine plus nalbuphine

Regional anesthesia / analgesia

Locations (1)

Asklepieion Hospital of Voula

Athens, Ελλάδα (+30), Greece